×

Biotech's $10 billion opportunity

1:34 PM ET Tue, 2 Sept 2014

CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.